Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Other Non-Current Liabilities (2022 - 2025)

TriSalus Life Sciences' Other Non-Current Liabilities history spans 4 years, with the latest figure at $10.1 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 37.06% year-over-year to $10.1 million; the TTM value through Dec 2025 reached $10.1 million, up 37.06%, while the annual FY2025 figure was $10.1 million, 37.06% up from the prior year.
  • Other Non-Current Liabilities reached $10.1 million in Q4 2025 per TLSIW's latest filing, up from $5.0 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $17.1 million in Q4 2023 to a low of $369000.0 in Q4 2022.
  • Average Other Non-Current Liabilities over 4 years is $8.5 million, with a median of $8.2 million recorded in 2025.
  • Peak YoY movement for Other Non-Current Liabilities: surged 4534.15% in 2023, then crashed 56.72% in 2024.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $369000.0 in 2022, then soared by 4534.15% to $17.1 million in 2023, then plummeted by 56.72% to $7.4 million in 2024, then soared by 37.06% to $10.1 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Other Non-Current Liabilities are $10.1 million (Q4 2025), $5.0 million (Q3 2025), and $10.0 million (Q2 2025).